Despite decades of research to develop effective treatments, the median survival for glioblastoma—the most common malignant primary brain tumor in adults—is just 15–18 months after diagnosis. One reason for this grim statistic is that these tumors invariably recur despite aggressive, multimodality treatments.
Nanoparticles extend glioblastoma survival in phase one trial
